Gloom Amidst Contract Research Boom
This article was originally published in PharmAsia News
According to conservative estimates, China's contract research organization market has hit 4 billion yuan and is expanding at 100 percent annually. However, the breakneck development is curtailed by the shortage of talent with practical experience, high investments in research facilities, and ignorance on intellectual property rights. Industry experts suggest that domestic CROs can succeed only when they ensure international-level education and training, proper legal structure, and focused marketing development. They should also form a more competitive local team and concentrate on early stage drug development, as well as preclinical and Phase I and II clinical trials to take advantage of domestic resources. (Click here for more)
You may also be interested in...
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.
Mylan and Pfizer’s Upjohn, already facing a delay to their proposed merger, may have to overcome regulatory barriers to get the deal over the line.
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.